<< Read Full Article
<< Read Full Article
Genentech Data Bring Jitters
- Loading Comments...
CHICAGO -- The annual meeting of the American Society of Clinical Oncology has traditionally been the forum where Genentech(DNA Quote) and its blockbuster cancer drug Avastin run away with best-in-show honors.
At this year's confab, however, Avastin is showing a bit of its age. It's still a hugely important drug, but clinical data presented lacked pizzazz:
A phase III lung cancer study of low and high doses of Avastin combined with a chemotherapy regimen popular in Europe showed equal efficacy and lower toxicity at the low dose. ...Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,309.92 | 1,091.49 | 2,138.44 | 32.31 |
Oil *
77.12
|
|
DOWN
154.48
|
DOWN
19.14
|
DOWN
37.61
|
DOWN
0.48
|
10 Yr
3.23%
SPDR Gold
115.06
|
|
-1.48%
|
-1.72%
|
-1.73%
|
-1.46%
|
Data delayed 20 minutes |


Connect with TheStreet